dc.contributor.author | Gorrini, C | |
dc.contributor.author | Mak, TW | |
dc.date.accessioned | 2020-09-30T13:39:35Z | |
dc.date.issued | 2019-02-11 | |
dc.identifier.citation | Cancer cell, 2019, 35 (2), pp. 161 - 163 | |
dc.identifier.issn | 1535-6108 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4103 | |
dc.identifier.eissn | 1878-3686 | |
dc.identifier.doi | 10.1016/j.ccell.2019.01.017 | |
dc.description.abstract | In this issue of Cancer Cell, Ogiwara et al. describe a novel link between the epigenetic regulator ARID1A and glutathione metabolism in cancer that is mediated by regulation of the cystine/glutamate transporter XCT. This work reveals that synthesis of reduced glutathione is a metabolic dependency of cancers with ARID1A-inactivating mutations. | |
dc.format | Print | |
dc.format.extent | 161 - 163 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | CELL PRESS | |
dc.subject | Humans | |
dc.subject | Neoplasms | |
dc.subject | Glutathione | |
dc.subject | Amino Acid Transport System y+ | |
dc.subject | Nuclear Proteins | |
dc.subject | Transcription Factors | |
dc.subject | Mutation | |
dc.title | Glutathione Metabolism: An Achilles' Heel of ARID1A-Deficient Tumors. | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1016/j.ccell.2019.01.017 | |
rioxxterms.licenseref.startdate | 2019-02 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Cancer cell | |
pubs.issue | 2 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Target Evaluation and Molecular Therapeutics | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Target Evaluation and Molecular Therapeutics | |
pubs.publication-status | Published | |
pubs.volume | 35 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Target Evaluation and Molecular Therapeutics | |
dc.contributor.icrauthor | Gorrini, Chiara | |